Sana Biotechnology, Inc. 8-K

What Happened
On March 3, 2026, Sana Biotechnology, Inc. (SANA) filed an 8‑K announcing that it issued a press release with its financial results for the quarter and year ended December 31, 2025 (the press release is attached as Exhibit 99.1). The same day the company entered into an amended and restated sales agreement with TD Securities (USA) LLC (TD Cowen) to act as sales agent for an at‑the‑market (ATM) offering of its common stock.

Key Details

• The Sales Agreement replaces the prior sales agreement dated May 8, 2025; under the prior agreement SANA sold ~11.3 million shares for net proceeds of about $45.8 million, leaving an unsold aggregate offering price of approximately $71.6 million.
• SANA will file a Registration Statement on Form S‑3 with a prospectus supplement for up to $150.0 million of common stock to be offered under the new Sales Agreement.
• TD Cowen may sell shares on the open market, in negotiated or block transactions, and will receive up to 3.0% of gross proceeds as compensation.
• The company is not obligated to sell any shares and may suspend or terminate the program; the Sales Agreement includes customary representations, indemnities, and termination rights.

Why It Matters
The 8‑K confirms Sana has reported its quarterly and year‑end results (investors should review the attached press release for the specific financial figures). The amended ATM sales agreement gives the company a flexible tool to raise up to $150 million of capital over time, which can support operations or R&D but would be dilutive to existing shareholders if shares are issued. Investors should watch for the detailed financial results in the press release and any announcements of actual ATM share sales, which can affect share count, supply in the market, and the stock price.